ArticleAnnals of internal medicine2024

In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.

Jin Ho Hwang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.